The company is scaling up manufacturing and commercial activities as it prepares to enter the U.S. market via the Food and Drug Administration’s de novo pathway.

Tasso, maker of at-home blood sample collection systems, is launching the next generation of its devices that aim to support patients enrolled in clinical trials and simplify their participation in ...

Novel innovations for stabilizing the plasma proteome in whole blood samples provide researchers with more confidence in their protein analysis. To reduce the preanalytical variability, scientists can ...

Shortly after securing an FDA clearance last month for its simple, self-operated blood sample collection device, Tasso has teamed up with Catapult Health to help propel its device into people’s homes.

The global blood collection devices market is set to grow from USD 9.13 billion in 2025 to USD 13.02 billion by 2030, with a ...

The plasma proteome is a rich source of potential biomarkers for diseases, such as cancer and neurodegenerative disorders. To assess these proteins, scientists commonly draw whole blood samples into ...